| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Diabetes Mellitus, Type 2 | 101 | 2021 | 6166 | 7.83 | Why? |
| Hypoglycemia | 19 | 2020 | 406 | 6.46 | Why? |
| Hypoglycemic Agents | 53 | 2021 | 2165 | 6.35 | Why? |
| Blood Glucose | 35 | 2020 | 3642 | 3.09 | Why? |
| Minority Groups | 12 | 2021 | 1631 | 2.86 | Why? |
| Glycated Hemoglobin A | 26 | 2021 | 1316 | 2.80 | Why? |
| Insulin | 18 | 2019 | 1316 | 2.73 | Why? |
| Diabetic Angiopathies | 6 | 2019 | 146 | 2.27 | Why? |
| Cardiovascular Diseases | 30 | 2021 | 11497 | 2.19 | Why? |
| Sulfonylurea Compounds | 7 | 2018 | 79 | 2.03 | Why? |
| Primary Health Care | 21 | 2020 | 4839 | 1.98 | Why? |
| Metabolic Diseases | 5 | 2021 | 505 | 1.97 | Why? |
| Diabetes Mellitus, Type 1 | 17 | 2021 | 1969 | 1.94 | Why? |
| Self-Management | 6 | 2020 | 546 | 1.83 | Why? |
| Obesity | 17 | 2021 | 7388 | 1.74 | Why? |
| Patient Education as Topic | 11 | 2020 | 1476 | 1.54 | Why? |
| Walking Speed | 2 | 2021 | 77 | 1.53 | Why? |
| Diabetes Complications | 11 | 2020 | 2358 | 1.36 | Why? |
| United Kingdom | 50 | 2021 | 18046 | 1.35 | Why? |
| Multimorbidity | 3 | 2020 | 703 | 1.22 | Why? |
| Diabetes Mellitus | 14 | 2021 | 8207 | 1.20 | Why? |
| England | 25 | 2021 | 5116 | 1.13 | Why? |
| Exercise | 19 | 2020 | 6771 | 1.12 | Why? |
| Hyperglycemia | 8 | 2021 | 1363 | 1.09 | Why? |
| Practice Patterns, Physicians' | 13 | 2020 | 4927 | 1.08 | Why? |
| Chronic Disease | 6 | 2021 | 5139 | 1.06 | Why? |
| Insulin Resistance | 6 | 2018 | 669 | 1.04 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2018 | 1510 | 1.03 | Why? |
| Biological Specimen Banks | 5 | 2020 | 1142 | 1.02 | Why? |
| Terminology as Topic | 2 | 2020 | 546 | 1.02 | Why? |
| Venous Thromboembolism | 6 | 2019 | 4273 | 1.01 | Why? |
| Body Mass Index | 18 | 2021 | 4306 | 1.00 | Why? |
| Observational Studies as Topic | 7 | 2021 | 1887 | 0.98 | Why? |
| Glucagon-Like Peptide-1 Receptor | 4 | 2018 | 138 | 0.97 | Why? |
| Metformin | 8 | 2021 | 640 | 0.94 | Why? |
| Guideline Adherence | 4 | 2017 | 2309 | 0.90 | Why? |
| Mortality | 11 | 2021 | 7132 | 0.89 | Why? |
| Adiposity | 4 | 2018 | 329 | 0.88 | Why? |
| Self Care | 5 | 2018 | 918 | 0.87 | Why? |
| Randomized Controlled Trials as Topic | 19 | 2019 | 10649 | 0.87 | Why? |
| Insulin, Long-Acting | 2 | 2019 | 30 | 0.86 | Why? |
| Diabetic Cardiomyopathies | 2 | 2018 | 79 | 0.83 | Why? |
| Funeral Rites | 1 | 2021 | 59 | 0.82 | Why? |
| Primary Prevention | 2 | 2018 | 778 | 0.82 | Why? |
| Actigraphy | 3 | 2019 | 102 | 0.82 | Why? |
| Evidence-Based Medicine | 6 | 2018 | 3228 | 0.82 | Why? |
| Humans | 214 | 2021 | 930598 | 0.81 | Why? |
| Group Processes | 2 | 2018 | 210 | 0.81 | Why? |
| Linagliptin | 1 | 2018 | 22 | 0.76 | Why? |
| Risk Factors | 53 | 2021 | 71621 | 0.75 | Why? |
| Glucose | 4 | 2020 | 573 | 0.74 | Why? |
| Secondary Prevention | 3 | 2018 | 762 | 0.73 | Why? |
| Waist-Hip Ratio | 1 | 2017 | 50 | 0.70 | Why? |
| Attitude of Health Personnel | 6 | 2021 | 4741 | 0.70 | Why? |
| Polypharmacy | 2 | 2017 | 347 | 0.69 | Why? |
| Fitness Trackers | 1 | 2018 | 120 | 0.69 | Why? |
| Induction Chemotherapy | 1 | 2018 | 149 | 0.69 | Why? |
| Accelerometry | 8 | 2021 | 228 | 0.69 | Why? |
| Cholesterol, LDL | 3 | 2018 | 499 | 0.69 | Why? |
| Symporters | 1 | 2017 | 80 | 0.67 | Why? |
| Religion | 1 | 2021 | 353 | 0.67 | Why? |
| Health Status Disparities | 9 | 2021 | 4072 | 0.66 | Why? |
| Prescription Drug Overuse | 1 | 2017 | 59 | 0.65 | Why? |
| Dyslipidemias | 3 | 2018 | 791 | 0.65 | Why? |
| Mandatory Programs | 1 | 2021 | 291 | 0.65 | Why? |
| Hand Strength | 1 | 2017 | 202 | 0.64 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2019 | 436 | 0.64 | Why? |
| Antidepressive Agents | 2 | 2019 | 509 | 0.63 | Why? |
| Diabetes, Gestational | 2 | 2018 | 426 | 0.63 | Why? |
| Research | 2 | 2020 | 2115 | 0.62 | Why? |
| Occupational Health | 3 | 2021 | 3965 | 0.60 | Why? |
| Health Personnel | 9 | 2021 | 29646 | 0.60 | Why? |
| Male | 109 | 2021 | 367725 | 0.58 | Why? |
| Blood Glucose Self-Monitoring | 3 | 2019 | 791 | 0.58 | Why? |
| Middle Aged | 89 | 2021 | 270681 | 0.58 | Why? |
| Medical Overuse | 1 | 2017 | 146 | 0.58 | Why? |
| Aged | 76 | 2021 | 215776 | 0.58 | Why? |
| Female | 109 | 2021 | 380317 | 0.58 | Why? |
| Peripheral Arterial Disease | 1 | 2021 | 471 | 0.57 | Why? |
| Insulins | 1 | 2014 | 26 | 0.57 | Why? |
| Fasting | 4 | 2020 | 555 | 0.56 | Why? |
| Evidence-Based Practice | 1 | 2021 | 693 | 0.56 | Why? |
| Receptors, Glucagon | 1 | 2014 | 8 | 0.56 | Why? |
| Healthy Lifestyle | 2 | 2018 | 447 | 0.56 | Why? |
| Medication Adherence | 5 | 2018 | 1270 | 0.54 | Why? |
| Glucagon-Like Peptide 1 | 1 | 2014 | 83 | 0.52 | Why? |
| Quality Improvement | 4 | 2018 | 2435 | 0.50 | Why? |
| Housing | 1 | 2021 | 1146 | 0.49 | Why? |
| Accidental Falls | 1 | 2017 | 448 | 0.49 | Why? |
| Posture | 4 | 2017 | 199 | 0.49 | Why? |
| Disease Management | 7 | 2020 | 6841 | 0.49 | Why? |
| Pneumonia, Viral | 25 | 2020 | 243684 | 0.49 | Why? |
| Coronavirus Infections | 25 | 2020 | 253789 | 0.48 | Why? |
| Residence Characteristics | 4 | 2021 | 1927 | 0.48 | Why? |
| Metabolic Syndrome | 1 | 2020 | 810 | 0.48 | Why? |
| Treatment Outcome | 31 | 2021 | 51732 | 0.47 | Why? |
| Health Priorities | 1 | 2020 | 959 | 0.46 | Why? |
| Family Characteristics | 3 | 2021 | 2551 | 0.46 | Why? |
| Vitamins | 1 | 2021 | 1208 | 0.45 | Why? |
| Patient Readmission | 2 | 2021 | 1543 | 0.45 | Why? |
| Pandemics | 43 | 2021 | 389249 | 0.45 | Why? |
| Cohort Studies | 21 | 2021 | 36005 | 0.44 | Why? |
| Cell Phone | 1 | 2018 | 750 | 0.43 | Why? |
| Risk Assessment | 17 | 2021 | 25439 | 0.43 | Why? |
| Betacoronavirus | 24 | 2020 | 204454 | 0.43 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.43 | Why? |
| Overweight | 1 | 2017 | 916 | 0.42 | Why? |
| General Practitioners | 1 | 2017 | 568 | 0.41 | Why? |
| Social Responsibility | 1 | 2014 | 363 | 0.40 | Why? |
| Blood Pressure | 5 | 2021 | 2198 | 0.39 | Why? |
| Heart Arrest | 1 | 2020 | 1239 | 0.39 | Why? |
| Albuminuria | 3 | 2019 | 164 | 0.38 | Why? |
| Adult | 56 | 2021 | 244371 | 0.38 | Why? |
| Uncertainty | 1 | 2020 | 1888 | 0.37 | Why? |
| Motor Activity | 3 | 2021 | 217 | 0.37 | Why? |
| Motivation | 3 | 2018 | 1640 | 0.36 | Why? |
| Dietary Supplements | 1 | 2021 | 2251 | 0.36 | Why? |
| Research Design | 6 | 2018 | 5830 | 0.36 | Why? |
| Respiratory Protective Devices | 1 | 2020 | 1637 | 0.36 | Why? |
| Depression | 5 | 2019 | 14116 | 0.36 | Why? |
| Depressive Disorder | 1 | 2019 | 1236 | 0.36 | Why? |
| Islam | 3 | 2021 | 545 | 0.35 | Why? |
| Global Health | 5 | 2020 | 13911 | 0.35 | Why? |
| Bariatric Surgery | 1 | 2018 | 1298 | 0.34 | Why? |
| Comorbidity | 15 | 2021 | 34796 | 0.34 | Why? |
| Incidence | 10 | 2020 | 25622 | 0.33 | Why? |
| Practice Guidelines as Topic | 7 | 2020 | 15421 | 0.33 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 9706 | 0.33 | Why? |
| Health Knowledge, Attitudes, Practice | 6 | 2018 | 8811 | 0.33 | Why? |
| Hospitalization | 11 | 2021 | 54280 | 0.33 | Why? |
| Cardiopulmonary Resuscitation | 1 | 2020 | 1876 | 0.32 | Why? |
| Inflammation | 3 | 2020 | 13255 | 0.32 | Why? |
| Prediabetic State | 3 | 2017 | 200 | 0.32 | Why? |
| Aged, 80 and over | 25 | 2021 | 88759 | 0.32 | Why? |
| Renal Insufficiency, Chronic | 2 | 2020 | 2654 | 0.32 | Why? |
| Walking | 4 | 2018 | 442 | 0.32 | Why? |
| Patient Selection | 2 | 2020 | 4560 | 0.31 | Why? |
| Liraglutide | 2 | 2018 | 47 | 0.31 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.31 | Why? |
| Canagliflozin | 4 | 2018 | 56 | 0.30 | Why? |
| Drug Therapy, Combination | 10 | 2019 | 7268 | 0.30 | Why? |
| Myocardial Infarction | 2 | 2018 | 3361 | 0.29 | Why? |
| Personal Protective Equipment | 2 | 2020 | 15978 | 0.29 | Why? |
| Prognosis | 12 | 2021 | 32490 | 0.29 | Why? |
| Delivery of Health Care, Integrated | 1 | 2017 | 1549 | 0.29 | Why? |
| Vitamin D | 1 | 2021 | 2904 | 0.29 | Why? |
| Stress, Psychological | 2 | 2020 | 10231 | 0.29 | Why? |
| Databases, Factual | 8 | 2021 | 6248 | 0.28 | Why? |
| Arrhythmias, Cardiac | 1 | 2018 | 2510 | 0.27 | Why? |
| Quarantine | 3 | 2021 | 18418 | 0.26 | Why? |
| Sodium-Glucose Transporter 2 | 3 | 2018 | 111 | 0.26 | Why? |
| Dementia | 1 | 2017 | 1861 | 0.26 | Why? |
| Time Factors | 15 | 2021 | 31397 | 0.25 | Why? |
| Biomarkers | 15 | 2019 | 23361 | 0.25 | Why? |
| Health Services Accessibility | 4 | 2021 | 10697 | 0.25 | Why? |
| Sleep | 3 | 2021 | 2695 | 0.25 | Why? |
| Mobile Applications | 1 | 2018 | 3032 | 0.24 | Why? |
| Longitudinal Studies | 8 | 2018 | 9893 | 0.24 | Why? |
| Diabetic Neuropathies | 2 | 2019 | 64 | 0.24 | Why? |
| Glomerular Filtration Rate | 2 | 2018 | 1262 | 0.23 | Why? |
| Young Adult | 20 | 2021 | 93724 | 0.23 | Why? |
| Case-Control Studies | 8 | 2021 | 17671 | 0.23 | Why? |
| Fear | 1 | 2017 | 3607 | 0.23 | Why? |
| Body Weight | 2 | 2018 | 1074 | 0.22 | Why? |
| Glucosides | 4 | 2018 | 359 | 0.22 | Why? |
| Neoplasms | 3 | 2020 | 17251 | 0.22 | Why? |
| Limb Salvage | 1 | 2021 | 124 | 0.22 | Why? |
| General Practice | 3 | 2019 | 718 | 0.22 | Why? |
| Europe | 8 | 2021 | 12702 | 0.21 | Why? |
| Heart Failure | 5 | 2019 | 6638 | 0.21 | Why? |
| Stroke | 3 | 2018 | 8839 | 0.21 | Why? |
| Benzhydryl Compounds | 3 | 2018 | 240 | 0.21 | Why? |
| Clinical Audit | 1 | 2021 | 204 | 0.21 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.21 | Why? |
| Cultural Competency | 1 | 2020 | 125 | 0.20 | Why? |
| Sex Factors | 8 | 2021 | 11014 | 0.20 | Why? |
| Censuses | 1 | 2021 | 172 | 0.20 | Why? |
| Shoes | 1 | 2019 | 10 | 0.20 | Why? |
| Cause of Death | 3 | 2018 | 4823 | 0.20 | Why? |
| Rest | 1 | 2020 | 188 | 0.20 | Why? |
| Health Promotion | 5 | 2018 | 2020 | 0.20 | Why? |
| Waist Circumference | 2 | 2017 | 199 | 0.20 | Why? |
| Retrospective Studies | 21 | 2021 | 105322 | 0.20 | Why? |
| Communicable Disease Control | 5 | 2021 | 29620 | 0.20 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.20 | Why? |
| Vaccination | 3 | 2021 | 19050 | 0.19 | Why? |
| Death Certificates | 1 | 2021 | 130 | 0.19 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.19 | Why? |
| Insulin Glargine | 1 | 2019 | 43 | 0.19 | Why? |
| Self Report | 3 | 2021 | 3802 | 0.19 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.19 | Why? |
| Sodium | 2 | 2018 | 309 | 0.19 | Why? |
| Wrist | 1 | 2018 | 37 | 0.18 | Why? |
| Resuscitation Orders | 1 | 2020 | 188 | 0.18 | Why? |
| Adolescent | 19 | 2021 | 86841 | 0.18 | Why? |
| Amputation | 1 | 2021 | 331 | 0.18 | Why? |
| Hypertension | 6 | 2020 | 8895 | 0.18 | Why? |
| Diabetic Foot | 2 | 2021 | 317 | 0.18 | Why? |
| Glucagon-Like Peptides | 1 | 2018 | 29 | 0.18 | Why? |
| Hydrochlorothiazide | 1 | 2018 | 31 | 0.18 | Why? |
| Cross-Sectional Studies | 18 | 2021 | 53120 | 0.18 | Why? |
| Communication Barriers | 1 | 2020 | 246 | 0.17 | Why? |
| Penile Erection | 1 | 2018 | 58 | 0.17 | Why? |
| Uracil | 1 | 2018 | 101 | 0.17 | Why? |
| Rosuvastatin Calcium | 1 | 2018 | 89 | 0.17 | Why? |
| Endocrinologists | 1 | 2018 | 67 | 0.17 | Why? |
| Exercise Movement Techniques | 1 | 2017 | 28 | 0.17 | Why? |
| Foot | 1 | 2019 | 195 | 0.17 | Why? |
| Self Concept | 2 | 2019 | 490 | 0.17 | Why? |
| Drug Resistance | 2 | 2017 | 395 | 0.17 | Why? |
| Multiple Chronic Conditions | 1 | 2018 | 115 | 0.17 | Why? |
| Survival Rate | 4 | 2020 | 9206 | 0.17 | Why? |
| Protective Factors | 3 | 2018 | 1720 | 0.17 | Why? |
| Electronic Health Records | 4 | 2018 | 3492 | 0.17 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2020 | 282 | 0.17 | Why? |
| Mental Disorders | 1 | 2020 | 6742 | 0.17 | Why? |
| Antihypertensive Agents | 3 | 2018 | 1962 | 0.17 | Why? |
| Peripheral Nervous System Diseases | 1 | 2019 | 193 | 0.17 | Why? |
| Prospective Studies | 13 | 2020 | 43301 | 0.17 | Why? |
| Attitude to Death | 1 | 2021 | 307 | 0.17 | Why? |
| Age Factors | 8 | 2021 | 21039 | 0.16 | Why? |
| Developed Countries | 1 | 2021 | 500 | 0.16 | Why? |
| Recreation | 1 | 2018 | 143 | 0.16 | Why? |
| Holidays | 1 | 2020 | 311 | 0.16 | Why? |
| Public Health | 2 | 2020 | 16359 | 0.16 | Why? |
| Medication Errors | 1 | 2017 | 107 | 0.16 | Why? |
| Glycation End Products, Advanced | 1 | 2017 | 72 | 0.16 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 350 | 0.16 | Why? |
| Drug Resistance, Multiple | 1 | 2017 | 156 | 0.16 | Why? |
| Medical Audit | 1 | 2017 | 218 | 0.16 | Why? |
| Environment Design | 1 | 2018 | 183 | 0.16 | Why? |
| Registries | 5 | 2020 | 12327 | 0.15 | Why? |
| Smoking | 3 | 2019 | 3358 | 0.15 | Why? |
| Sample Size | 1 | 2018 | 518 | 0.15 | Why? |
| Community-Institutional Relations | 1 | 2017 | 164 | 0.15 | Why? |
| Child Welfare | 1 | 2021 | 405 | 0.15 | Why? |
| Community Health Services | 2 | 2017 | 1000 | 0.15 | Why? |
| Lower Extremity | 1 | 2021 | 593 | 0.15 | Why? |
| Family Practice | 1 | 2002 | 472 | 0.15 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.15 | Why? |
| Product Surveillance, Postmarketing | 1 | 2018 | 189 | 0.15 | Why? |
| Urban Health | 1 | 2018 | 382 | 0.15 | Why? |
| Weight Loss | 2 | 2018 | 826 | 0.15 | Why? |
| Prevalence | 6 | 2020 | 25773 | 0.14 | Why? |
| Postnatal Care | 1 | 2018 | 346 | 0.14 | Why? |
| Tetrazoles | 1 | 2018 | 262 | 0.14 | Why? |
| Health Behavior | 5 | 2020 | 4449 | 0.14 | Why? |
| Upper Extremity | 1 | 2017 | 193 | 0.14 | Why? |
| Benzimidazoles | 1 | 2018 | 275 | 0.14 | Why? |
| Multicenter Studies as Topic | 2 | 2019 | 2437 | 0.14 | Why? |
| Meta-Analysis as Topic | 2 | 2021 | 1289 | 0.14 | Why? |
| Patient Satisfaction | 3 | 2017 | 2517 | 0.14 | Why? |
| Early Medical Intervention | 1 | 2018 | 487 | 0.14 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.14 | Why? |
| Life Style | 3 | 2018 | 2708 | 0.14 | Why? |
| Interdisciplinary Communication | 2 | 2019 | 1425 | 0.14 | Why? |
| Physical Fitness | 1 | 2017 | 334 | 0.13 | Why? |
| Heart Diseases | 1 | 2011 | 3503 | 0.13 | Why? |
| Child Behavior | 1 | 2017 | 266 | 0.13 | Why? |
| Patient Admission | 2 | 2021 | 5250 | 0.13 | Why? |
| Linear Models | 2 | 2018 | 1914 | 0.13 | Why? |
| Health Status | 5 | 2019 | 3259 | 0.13 | Why? |
| School Health Services | 1 | 2018 | 294 | 0.13 | Why? |
| Ischemic Attack, Transient | 1 | 2018 | 439 | 0.13 | Why? |
| Physicians, Primary Care | 1 | 2017 | 298 | 0.13 | Why? |
| Cost-Benefit Analysis | 5 | 2018 | 2259 | 0.13 | Why? |
| Mental Health | 1 | 2020 | 15770 | 0.13 | Why? |
| Delivery of Health Care | 5 | 2021 | 15909 | 0.13 | Why? |
| Text Messaging | 1 | 2018 | 389 | 0.13 | Why? |
| Cardiorespiratory Fitness | 1 | 2017 | 313 | 0.13 | Why? |
| Multiple Organ Failure | 2 | 2021 | 1724 | 0.13 | Why? |
| Population Surveillance | 2 | 2020 | 4967 | 0.13 | Why? |
| Interpersonal Relations | 1 | 2021 | 926 | 0.13 | Why? |
| Regression Analysis | 2 | 2017 | 2484 | 0.13 | Why? |
| Diagnostic Self Evaluation | 1 | 2017 | 394 | 0.13 | Why? |
| State Medicine | 5 | 2021 | 2847 | 0.12 | Why? |
| Measles | 1 | 2020 | 608 | 0.12 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.12 | Why? |
| Ischemia | 1 | 2021 | 901 | 0.12 | Why? |
| Program Evaluation | 2 | 2019 | 1929 | 0.12 | Why? |
| C-Reactive Protein | 3 | 2017 | 7972 | 0.12 | Why? |
| Risk Management | 1 | 2020 | 1044 | 0.12 | Why? |
| Intermediate Care Facilities | 1 | 2012 | 59 | 0.12 | Why? |
| Vaccination Refusal | 1 | 2021 | 831 | 0.12 | Why? |
| Empathy | 1 | 2019 | 658 | 0.12 | Why? |
| Cardiac Rehabilitation | 1 | 2018 | 525 | 0.12 | Why? |
| Child | 10 | 2021 | 70012 | 0.12 | Why? |
| Quality Indicators, Health Care | 1 | 2017 | 580 | 0.12 | Why? |
| Early Diagnosis | 2 | 2018 | 2443 | 0.12 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.11 | Why? |
| Combined Modality Therapy | 2 | 2018 | 3395 | 0.11 | Why? |
| Personal Satisfaction | 1 | 2021 | 1243 | 0.11 | Why? |
| Piperidines | 1 | 2018 | 795 | 0.11 | Why? |
| Down-Regulation | 1 | 2018 | 1416 | 0.11 | Why? |
| Age Distribution | 2 | 2018 | 3567 | 0.11 | Why? |
| Severity of Illness Index | 6 | 2021 | 48226 | 0.11 | Why? |
| Patient Compliance | 2 | 2018 | 1468 | 0.11 | Why? |
| Social Behavior | 1 | 2020 | 882 | 0.11 | Why? |
| Healthcare Disparities | 3 | 2020 | 3893 | 0.11 | Why? |
| Disasters | 1 | 2020 | 760 | 0.11 | Why? |
| Follow-Up Studies | 6 | 2021 | 17020 | 0.11 | Why? |
| Informed Consent | 1 | 2018 | 890 | 0.11 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.11 | Why? |
| Proportional Hazards Models | 2 | 2021 | 6543 | 0.11 | Why? |
| Epidemiologic Methods | 1 | 2014 | 392 | 0.11 | Why? |
| Morbidity | 1 | 2017 | 1426 | 0.11 | Why? |
| Workflow | 1 | 2020 | 2373 | 0.11 | Why? |
| Risk | 3 | 2018 | 5288 | 0.11 | Why? |
| Cooperative Behavior | 1 | 2018 | 1216 | 0.10 | Why? |
| Renal Insufficiency | 1 | 2018 | 810 | 0.10 | Why? |
| Coronary Disease | 1 | 2016 | 645 | 0.10 | Why? |
| Socioeconomic Factors | 4 | 2021 | 8495 | 0.10 | Why? |
| Patient-Centered Care | 1 | 2019 | 860 | 0.10 | Why? |
| Surveys and Questionnaires | 5 | 2021 | 43792 | 0.10 | Why? |
| Depressive Disorder, Major | 1 | 2019 | 852 | 0.10 | Why? |
| Clinical Trials as Topic | 2 | 2020 | 7330 | 0.10 | Why? |
| Exercise Therapy | 1 | 2018 | 976 | 0.10 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.10 | Why? |
| United States | 8 | 2021 | 46150 | 0.10 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.09 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.09 | Why? |
| Acceleration | 2 | 2018 | 26 | 0.09 | Why? |
| Physician's Role | 1 | 2018 | 853 | 0.09 | Why? |
| Heart Rate | 1 | 2018 | 1527 | 0.09 | Why? |
| Social Determinants of Health | 1 | 2021 | 1757 | 0.09 | Why? |
| African Americans | 2 | 2021 | 3363 | 0.09 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.09 | Why? |
| Qualitative Research | 1 | 2021 | 4337 | 0.09 | Why? |
| Software | 2 | 2018 | 2501 | 0.09 | Why? |
| Thromboembolism | 1 | 2021 | 2101 | 0.09 | Why? |
| Health Records, Personal | 1 | 2009 | 63 | 0.09 | Why? |
| Workplace | 1 | 2021 | 2075 | 0.09 | Why? |
| Postprandial Period | 2 | 2017 | 45 | 0.09 | Why? |
| Internationality | 2 | 2018 | 3297 | 0.09 | Why? |
| Caribbean Region | 2 | 2020 | 349 | 0.09 | Why? |
| World Health Organization | 2 | 2018 | 4213 | 0.09 | Why? |
| Wales | 2 | 2021 | 758 | 0.09 | Why? |
| Statistics, Nonparametric | 1 | 2011 | 1008 | 0.09 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.09 | Why? |
| Asia | 3 | 2020 | 2399 | 0.09 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.08 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.08 | Why? |
| Family | 1 | 2021 | 2909 | 0.08 | Why? |
| Infant | 5 | 2021 | 30274 | 0.08 | Why? |
| Consensus | 2 | 2018 | 6345 | 0.08 | Why? |
| Sleep Wake Disorders | 1 | 2018 | 1463 | 0.08 | Why? |
| Anxiety Disorders | 1 | 2019 | 2290 | 0.08 | Why? |
| Infant, Newborn | 4 | 2021 | 23105 | 0.08 | Why? |
| Renin-Angiotensin System | 2 | 2020 | 3661 | 0.08 | Why? |
| Behavior Therapy | 2 | 2019 | 235 | 0.07 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.07 | Why? |
| Health Surveys | 1 | 2017 | 2841 | 0.07 | Why? |
| Child, Preschool | 5 | 2021 | 36283 | 0.07 | Why? |
| Health Care Surveys | 2 | 2007 | 2942 | 0.07 | Why? |
| Interviews as Topic | 1 | 2014 | 1952 | 0.07 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.07 | Why? |
| Quality of Life | 4 | 2018 | 9820 | 0.07 | Why? |
| Time-to-Treatment | 2 | 2019 | 5883 | 0.07 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.07 | Why? |
| Algorithms | 2 | 2020 | 7346 | 0.07 | Why? |
| Guidelines as Topic | 1 | 2018 | 2844 | 0.07 | Why? |
| Skin | 1 | 2017 | 2096 | 0.07 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.07 | Why? |
| Influenza Vaccines | 1 | 2020 | 2941 | 0.07 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.07 | Why? |
| Acute Coronary Syndrome | 1 | 2018 | 2107 | 0.07 | Why? |
| Aerosols | 1 | 2020 | 5393 | 0.07 | Why? |
| Canada | 1 | 2017 | 6018 | 0.07 | Why? |
| Electrocardiography | 1 | 2018 | 3957 | 0.07 | Why? |
| Coronary Artery Disease | 1 | 2018 | 2570 | 0.06 | Why? |
| Decision Making | 1 | 2018 | 3132 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3832 | 0.06 | Why? |
| Patient Safety | 1 | 2018 | 4885 | 0.06 | Why? |
| Quality of Health Care | 3 | 2021 | 1948 | 0.06 | Why? |
| Semantic Web | 1 | 2021 | 53 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Propensity Score | 2 | 2021 | 2690 | 0.05 | Why? |
| Predictive Value of Tests | 4 | 2019 | 9537 | 0.05 | Why? |
| Aging | 1 | 2017 | 3581 | 0.05 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.05 | Why? |
| Risk Reduction Behavior | 2 | 2018 | 946 | 0.05 | Why? |
| Pregnancy | 3 | 2018 | 23879 | 0.05 | Why? |
| Dehydration | 1 | 2020 | 51 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2019 | 5002 | 0.05 | Why? |
| Ketosis | 1 | 2020 | 44 | 0.05 | Why? |
| Internet | 1 | 2018 | 6204 | 0.05 | Why? |
| Poisson Distribution | 1 | 2021 | 348 | 0.05 | Why? |
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2020 | 58 | 0.05 | Why? |
| Diet Therapy | 1 | 2020 | 66 | 0.05 | Why? |
| Social Class | 2 | 2019 | 1360 | 0.05 | Why? |
| Body Weights and Measures | 1 | 2019 | 50 | 0.05 | Why? |
| Education, Distance | 1 | 2020 | 4956 | 0.05 | Why? |
| Physicians, Family | 1 | 2002 | 208 | 0.05 | Why? |
| Social Media | 1 | 2021 | 5798 | 0.05 | Why? |
| Contraindications, Drug | 1 | 2020 | 281 | 0.05 | Why? |
| Drug Monitoring | 2 | 2017 | 1408 | 0.05 | Why? |
| Libido | 1 | 2018 | 32 | 0.05 | Why? |
| Pharmacokinetics | 1 | 2018 | 41 | 0.05 | Why? |
| Scandinavian and Nordic Countries | 1 | 2018 | 96 | 0.05 | Why? |
| Air Pollution | 1 | 2017 | 3504 | 0.04 | Why? |
| Survival Analysis | 2 | 2021 | 7592 | 0.04 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.04 | Why? |
| Consensus Development Conferences as Topic | 1 | 2018 | 93 | 0.04 | Why? |
| Sri Lanka | 1 | 2018 | 241 | 0.04 | Why? |
| Drug Administration Schedule | 2 | 2019 | 2324 | 0.04 | Why? |
| Berlin | 1 | 2018 | 283 | 0.04 | Why? |
| Comparative Effectiveness Research | 1 | 2018 | 178 | 0.04 | Why? |
| Sexuality | 1 | 2018 | 85 | 0.04 | Why? |
| Electronic Prescribing | 1 | 2017 | 60 | 0.04 | Why? |
| Memory | 1 | 2018 | 137 | 0.04 | Why? |
| Biphenyl Compounds | 1 | 2018 | 249 | 0.04 | Why? |
| Leptin | 1 | 2017 | 141 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2018 | 673 | 0.04 | Why? |
| Television | 1 | 2018 | 224 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Triglycerides | 1 | 2019 | 478 | 0.04 | Why? |
| Asia, Southeastern | 1 | 2017 | 390 | 0.04 | Why? |
| Glucose Tolerance Test | 1 | 2017 | 238 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Lipoproteins, HDL | 1 | 2017 | 154 | 0.04 | Why? |
| Cholesterol, HDL | 1 | 2019 | 439 | 0.04 | Why? |
| Models, Economic | 1 | 2018 | 316 | 0.04 | Why? |
| Network Meta-Analysis | 1 | 2018 | 426 | 0.04 | Why? |
| Eligibility Determination | 1 | 2017 | 255 | 0.04 | Why? |
| Medical Records | 1 | 2018 | 513 | 0.04 | Why? |
| Optical Imaging | 1 | 2017 | 197 | 0.04 | Why? |
| Fluid Therapy | 1 | 2020 | 628 | 0.04 | Why? |
| Proof of Concept Study | 1 | 2017 | 696 | 0.04 | Why? |
| Blood Pressure Determination | 1 | 2018 | 450 | 0.04 | Why? |
| Automobile Driving | 1 | 2018 | 222 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2019 | 657 | 0.03 | Why? |
| Body Composition | 1 | 2018 | 414 | 0.03 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| Nitrogen Dioxide | 1 | 2017 | 488 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.03 | Why? |
| Quality-Adjusted Life Years | 1 | 2017 | 511 | 0.03 | Why? |
| Focus Groups | 1 | 2017 | 811 | 0.03 | Why? |
| Immunization Schedule | 1 | 2021 | 1305 | 0.03 | Why? |
| National Health Programs | 1 | 2020 | 807 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2018 | 694 | 0.03 | Why? |
| Policy | 1 | 2021 | 1372 | 0.03 | Why? |
| Norway | 1 | 2017 | 1004 | 0.03 | Why? |
| Monitoring, Ambulatory | 1 | 2017 | 343 | 0.03 | Why? |
| Oxygen Consumption | 1 | 2017 | 711 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2021 | 1061 | 0.03 | Why? |
| Psychiatric Status Rating Scales | 1 | 2019 | 1340 | 0.03 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.03 | Why? |
| Bangladesh | 1 | 2018 | 1620 | 0.03 | Why? |
| Diabetic Ketoacidosis | 1 | 2020 | 622 | 0.03 | Why? |
| Insurance, Health | 1 | 2018 | 634 | 0.03 | Why? |
| Schools | 2 | 2018 | 4187 | 0.03 | Why? |
| Child Health | 1 | 2021 | 940 | 0.03 | Why? |
| Vaccination Coverage | 1 | 2021 | 1249 | 0.03 | Why? |
| Exercise Test | 1 | 2018 | 911 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.03 | Why? |
| Sex Distribution | 1 | 2018 | 2083 | 0.03 | Why? |
| Policy Making | 1 | 2018 | 829 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Health Services Research | 1 | 2017 | 756 | 0.03 | Why? |
| Spain | 2 | 2021 | 15545 | 0.03 | Why? |
| Pakistan | 1 | 2018 | 2302 | 0.03 | Why? |
| Health | 1 | 2011 | 130 | 0.03 | Why? |
| Sweden | 1 | 2017 | 1969 | 0.03 | Why? |
| Congresses as Topic | 1 | 2019 | 1347 | 0.02 | Why? |
| Denmark | 1 | 2017 | 2654 | 0.02 | Why? |
| Vocabulary, Controlled | 1 | 2009 | 26 | 0.02 | Why? |
| Social Perception | 1 | 2013 | 371 | 0.02 | Why? |
| Health Expenditures | 1 | 2017 | 904 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Referral and Consultation | 2 | 2017 | 4816 | 0.02 | Why? |
| Republic of Korea | 1 | 2021 | 5858 | 0.02 | Why? |
| Mass Screening | 2 | 2019 | 8005 | 0.02 | Why? |
| Stroke Volume | 1 | 2017 | 2153 | 0.02 | Why? |
| Medical Records Systems, Computerized | 1 | 2009 | 159 | 0.02 | Why? |
| Self Efficacy | 1 | 2013 | 717 | 0.02 | Why? |
| Insulin Infusion Systems | 1 | 2009 | 256 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Oxidative Stress | 1 | 2017 | 2050 | 0.02 | Why? |
| Australia | 1 | 2019 | 6306 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2017 | 3444 | 0.02 | Why? |
| Particulate Matter | 1 | 2017 | 3249 | 0.02 | Why? |
| Health Care Costs | 1 | 2012 | 1007 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Models, Statistical | 1 | 2021 | 5312 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2017 | 3755 | 0.02 | Why? |
| Health Resources | 1 | 2017 | 2592 | 0.02 | Why? |
| Communication | 1 | 2020 | 5206 | 0.01 | Why? |
| Germany | 1 | 2017 | 9196 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| India | 1 | 2018 | 11875 | 0.01 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.01 | Why? |
| Interleukin-6 | 1 | 2017 | 7522 | 0.01 | Why? |
| Air Pollutants | 1 | 2017 | 3110 | 0.01 | Why? |
| Patient Care Team | 1 | 2012 | 3556 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Diagnosis, Differential | 1 | 2009 | 7220 | 0.01 | Why? |